# Ipamorelin Dosage in the Research: Doses, Half-Life & Routes > Ipamorelin dosage as studied, not prescribed: the doses and routes used in published human and animal research, its ~2-hour half-life, and the unapproved regulatory status. The doses and routes used in the published human and animal literature, the pharmacokinetics, and the regulatory status — described, never recommended. ## The short version This page describes the Ipamorelin doses that appear in published studies. It is not a how-to and not a recommendation — it reports what researchers gave to people and animals, in what amounts, by what route, and what happened. Because ipamorelin is not an approved medicine, there is no official human dose, no label, and no prescribing guidance anywhere. In plain terms: the human studies used intravenous (into-the-vein) dosing in carefully controlled settings. The animal studies used a mix of routes. The combinations people share online — usually pairing ipamorelin with CJC-1295 and injecting under the skin — have no published human dosing basis at all and are described in community forums, not in trials. Everything below is third-person and study-attributed. No dose here should be read as a target. ## Doses used in the published studies In human research, ipamorelin was given intravenously. The pharmacokinetic study used single IV infusions of 4.21 to 140.45 nmol/kg over 15 minutes in healthy male volunteers [2]. The Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to seven days in bowel-resection patients [3]. In animals, the doses and routes varied with the model. The rat bone-growth study used 18, 90, and 450 microg/day subcutaneously, divided three times daily, for 15 days [4]. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally [5]. None of these is a human protocol; they are the conditions under which specific outcomes were measured, in specific species [4][5]. Community "stack" protocols that pair ipamorelin with CJC-1295 by subcutaneous injection have no peer-reviewed human dosing basis and should be read as anecdotal, not as anything established. ## Half-life and pharmacokinetics Ipamorelin's terminal half-life in healthy human volunteers is approximately two hours (IV), with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The kinetics were dose-proportional across the range tested, and the growth-hormone response was a single discrete pulse peaking around 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance is roughly five-fold lower than GHRP-6. The short half-life and single-pulse GH response are the most reliable pharmacokinetic facts on record [2]. ## Is ipamorelin fda approved No. For the question "is ipamorelin fda approved," the answer is unambiguous: ipamorelin has never been approved by the FDA — or any other regulatory authority — for any indication [3]. It was investigated for postoperative ileus but the Phase 2 trial missed its endpoint and development did not continue [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, tightening compounding-pharmacy access. It is marketed only as a research chemical, and it is prohibited in sport at all times under WADA category S2. ## What is cjc-1295 ipamorelin "What is cjc-1295 ipamorelin" refers to a two-peptide pairing, not a single drug. Ipamorelin is a ghrelin-receptor agonist that releases growth hormone through GHS-R1a; CJC-1295 is a separate GHRH analog that acts on the GHRH receptor [1]. People combine them because the two receptors drive GH release by complementary pathways [1]. Important caveat: the pairing has never been tested as a combination in any controlled trial — its rationale is the separate pharmacology of each peptide, and any specific combined preparation is a community practice, not an evidence-based product [3]. ## How much cjc-1295 ipamorelin should i take For "how much cjc-1295 ipamorelin should i take," this review cannot and will not provide a dose — there is no established or approved human dose for ipamorelin, alone or combined with CJC-1295 [3]. No controlled human trial has tested the combination for any outcome, so no dose has clinical support. What the literature offers instead is context: ipamorelin's human studies used intravenous dosing in controlled settings [2][3], and the popular subcutaneous stack circulating online has no peer-reviewed dosing basis. ## Is cjc-1295 ipamorelin safe The honest answer to "is cjc-1295 ipamorelin safe" is that the combination's safety has not been characterized in any controlled human trial [3]. For ipamorelin alone, the seven-day Phase 2 trial showed no ipamorelin-specific safety signal in that short window [3], but there is no long-term human safety database, and a class-level cardiotoxicity signal exists from a 28-day study of a different ghrelin-receptor agonist in rats [6]. Adding a second peptide (CJC-1295) only widens the evidence gap. The cited cautions on [the effects page](/effects) cover this in detail. ## How to reconstitute cjc-1295 ipamorelin 5mg The phrase "how to reconstitute cjc-1295 ipamorelin 5mg" comes up because these peptides ship as a lyophilized (freeze-dried) powder that must be dissolved before any research handling. In general peptide-handling terms drawn from the research-supply literature, lyophilized peptide is reconstituted with bacteriostatic water, and as a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general handling observations, not a clinical preparation instruction or a dosing protocol — ipamorelin has no approved human preparation [3]. --- A long-form evidence review of the ipamorelin record read through its gut and appetite biology — the founding selectivity data weighed against the single failed human trial, and the word 'reviews' meaning only that the literature is appraised, never that a clinic, a vendor, or a prescription stands behind it.